Rifadin and Septa Pediatric

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Using rifAMPin together with sulfamethoxazole may alter the effects of both medications and cause serious side effects that may affect your liver. Call your doctor immediately if you experience a fever, chills, joint pain or swelling, excessive tiredness or weakness, unusual bleeding or bruising, skin rash or itching, loss of appetite, nausea, vomiting, or yellowing of the skin or the whites of your eyes. You should also contact your doctor if your infection worsens. If your doctor does prescribe these medications together, you may need a dose adjustment or special tests to safely take both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

MONITOR: During coadministration of rifampin and sulfamethoxazole-trimethoprim (SMX-TMP), the serum concentrations of rifampin may be increased while those of SMX and TMP may be decreased. In a study of 15 tuberculosis patients treated with rifampin for at least two weeks, SMX-TMP given for 5 to 10 days increased the median peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) of rifampin by 31% and 60%, respectively. The mechanism of interaction has not been established. In another study of 10 HIV-infected patients receiving SMX-TMP prophylaxis (800 mg-160 mg orally once a day) for at least one month, antituberculosis therapy containing rifampin (600 mg/day) given for more than 12 days decreased the mean AUC of SMX by 23% and that of TMP by 47%, most likely due to induction of hepatic microsomal enzymes by rifampin. The clinical significance of this interaction is unknown but may be greater with low dosages of SMX-TMP. A case-control study evaluating the effect of SMX-TMP dosage on the risk of toxoplasmosis suggest that rifampin exposure may reduce the efficacy of SMX-TMP prophylaxis.

MANAGEMENT: Patients receiving rifampin and SMX-TMP should be monitored for potentially increased toxicity of rifampin. Patients should be advised to notify their physician if they experience signs and symptoms of hepatotoxicity such as fever, rash, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, and jaundice. In addition, the possibility of reduced efficacy of SMX-TMP should be considered, particularly when used for prevention of toxoplasmic encephalitis in HIV patients because adequate drug levels are required in the central nervous system. It may be advisable to refrain from low-dose prophylactic regimens (less than 4 DS tablets per week).

Rifadin

Generic Name: rifampin

Brand name: Rifadin, Rifadin IV, Rimactane

Synonyms: n.a.

What is Rifadin?

Septa Pediatric

Generic Name: sulfamethoxazole / trimethoprim

Brand name: Bactrim, Bactrim DS, Bactrim IV, Septra IV, SMZ-TMP DS, Sulfatrim Pediatric, Septra, Sulfatrim, Bethaprim, Cotrim, Uroplus, Uroplus DS, Cotrim DS, Bactrim Pediatric, Bethaprim Pediatric, Sulfatrim Suspension, Cotrim Pediatric, Septra DS

Synonyms: Sulfamethoxazole and trimethoprim, Sulfamethoxazole and Trimethoprim

What is Septa Pediatric?